132 related articles for article (PubMed ID: 1568578)
1. Spironolactone pharmacokinetics and pharmacodynamics in patients with cirrhotic ascites.
Sungaila I; Bartle WR; Walker SE; DeAngelis C; Uetrecht J; Pappas C; Vidins E
Gastroenterology; 1992 May; 102(5):1680-5. PubMed ID: 1568578
[TBL] [Abstract][Full Text] [Related]
2. New insights into the pharmacokinetics of spironolactone.
Overdiek HW; Hermens WA; Merkus FW
Clin Pharmacol Ther; 1985 Oct; 38(4):469-74. PubMed ID: 4042530
[TBL] [Abstract][Full Text] [Related]
3. Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolites.
Gardiner P; Schrode K; Quinlan D; Martin BK; Boreham DR; Rogers MS; Stubbs K; Smith M; Karim A
J Clin Pharmacol; 1989 Apr; 29(4):342-7. PubMed ID: 2723123
[TBL] [Abstract][Full Text] [Related]
4. Analysis of metabolites--a new approach to bioequivalence studies of spironolactone formulations.
Vergin H; Mahr G; Metz R; Eichinger A; Nitsche V; Martens H
Int J Clin Pharmacol Ther; 1997 Aug; 35(8):334-40. PubMed ID: 9266289
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of an HPLC method for the determination of spironolactone and its metabolites in paediatric plasma samples.
Sandall JM; Millership JS; Collier PS; McElnay JC
J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Jul; 839(1-2):36-44. PubMed ID: 16510319
[TBL] [Abstract][Full Text] [Related]
6. Influence of food on the bioavailability of spironolactone.
Overdiek HW; Merkus FW
Clin Pharmacol Ther; 1986 Nov; 40(5):531-6. PubMed ID: 3769384
[TBL] [Abstract][Full Text] [Related]
7. High-performance liquid chromatography methods for the separation and quantitation of spironolactone and its degradation products in aqueous formulations and of its metabolites in rat serum.
Kaukonen AM; Vuorela P; Vuorela H; Mannermaa JP
J Chromatogr A; 1998 Feb; 797(1-2):271-81. PubMed ID: 9542120
[TBL] [Abstract][Full Text] [Related]
8. The metabolism and biopharmaceutics of spironolactone in man.
Overdiek HW; Merkus FW
Rev Drug Metab Drug Interact; 1987; 5(4):273-302. PubMed ID: 3333882
[TBL] [Abstract][Full Text] [Related]
9. Water-soluble beta-cyclodextrins in paediatric oral solutions of spironolactone: preclinical evaluation of spironolactone bioavailability from solutions of beta-cyclodextrin derivatives in rats.
Kaukonen AM; Lennernäs H; Mannermaa JP
J Pharm Pharmacol; 1998 Jun; 50(6):611-9. PubMed ID: 9680070
[TBL] [Abstract][Full Text] [Related]
10. Determination of the serum concentration of spironolactone and its metabolites by high-performance liquid chromatography.
Overdiek JW; Hermens WA; Merkus FW
J Chromatogr; 1985 Jun; 341(2):279-85. PubMed ID: 4030980
[TBL] [Abstract][Full Text] [Related]
11. Investigation on the bioequivalence of 2 oral preparations containing spironolactone and furosemide.
Vergin H; Mahr G; Metz R; Eichinger A; Nitsche V
Int J Clin Pharmacol Ther; 1998 Apr; 36(4):231-8. PubMed ID: 9587051
[TBL] [Abstract][Full Text] [Related]
12. Canrenone and androgen receptor-active materials in plasma of cirrhotic patients during long-term K-canrenoate or spironolactone therapy.
Andriulli A; Arrigoni A; Gindro T; Karbowiak I; Buzzetti G; Armanini D
Digestion; 1989; 44(3):155-62. PubMed ID: 2697627
[TBL] [Abstract][Full Text] [Related]
13. Exploration of sodium homeostasis and pharmacokinetics in bile duct-ligated rats treated by anti-cirrhosis herbal formula plus spironolactone.
Hsueh TP; Tsai TH
Front Pharmacol; 2023; 14():1092657. PubMed ID: 36744253
[TBL] [Abstract][Full Text] [Related]
14. Reassessment of cross-reactivity of spironolactone metabolites with four digoxin immunoassays.
Pleasants RA; Williams DM; Porter RS; Gadsden RH
Ther Drug Monit; 1989; 11(2):200-4. PubMed ID: 2655203
[TBL] [Abstract][Full Text] [Related]
15. [Pharmacokinetic studies and bioavailability of bendroflumethiazide in combination with spironolactone].
Vergin H; Nuss U; Strobel K
Arzneimittelforschung; 1986 Mar; 36(3):490-5. PubMed ID: 3707669
[TBL] [Abstract][Full Text] [Related]
16. Bioequivalence between two furosemide-spironolactone formulations: a pharmacokinetic and pharmacodynamic approach.
Schütz W; Freissmuth M; Tuisl E; Blöchl-Daum B; Eichler HG; Loew D
Curr Med Res Opin; 1991; 12(7):450-8. PubMed ID: 1778087
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of canrenone and metabolites after base hydrolysis following single and multiple dose oral administration of spironolactone.
Ho PC; Bourne DW; Triggs EJ; Heazlewood V
Eur J Clin Pharmacol; 1984; 27(4):441-6. PubMed ID: 6519151
[TBL] [Abstract][Full Text] [Related]
18. Preclinical study of simultaneous pharmacokinetic and pharmacodynamic herb-drug interactions between Yin-Chen-Hao-Tang and spironolactone.
Hsueh TP; Tsai TH
BMC Complement Med Ther; 2020 Aug; 20(1):253. PubMed ID: 32799863
[TBL] [Abstract][Full Text] [Related]
19. Hepatic metabolism of spironolactone. Production of 3-hydroxy-thiomethyl metabolites.
Los LE; Pitzenberger SM; Ramjit HG; Coddington AB; Colby HD
Drug Metab Dispos; 1994; 22(6):903-8. PubMed ID: 7895608
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of oral spironolactone in infants up to 2 years of age.
Lass J; Leroux S; Kõrgvee LT; Varendi H; Kipper K; Takkis K; Aro R; Metsvaht T; Oselin K; Pfister M; Soeorg H; van den Anker J; Lutsar I
Eur J Clin Pharmacol; 2024 Feb; 80(2):239-248. PubMed ID: 38041740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
